Radnostix, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.6M
- Price
- $0.054
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.00%
- Volume
- 62.1K
About
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
Quick stats
Shares outstanding529.2M
Computed float82.3M
Float / shares15.6%
Cash runway (months)35.8
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001038277
Websitehttps://radnostix.com
AI Summary
AI-generated1/5
majorbullishm and a
Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear
Radnostix (formerly International Isotopes) signed a definitive agreement to sell its DUF6 deconversion and fluorine extraction assets, including an NRC 10 CFR Part 40 license, to NANO Nuclear Energy for $9.5 million in cash plus $4.0 million in NNE stock.
Closing is expected in roughly 90 to 120 days but depends on NRC consent to the license transfer and other approvals, including from New Mexico officials.
Management plans to use proceeds to accelerate its four radioisotope technology segments in medical and industrial applications while retaining upside via the NNE stock consideration.
Red flags
- closing contingent on NRC license-transfer consent and other regulatory approvals
- licensed facility was never constructed; value rests on license and IP
- part of consideration is in acquirer stock, exposing INIS to NNE price risk